ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Top Stocks Set to Outperform
Over the Next 1 to 3 Months.
Click for your free picks >>

Quote:

Search for Ticker

Free Membership

Search:

ZMH: Zimmer Hldgs Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ZIMMER HLDGS INC (NYSE)
ZMH	58.33	0.37	(0.64%)	Vol. 1,429,649	15:59 ET

Zimmer is a global leader in the design, development, manufacturing and market of reconstructive orthopaedic implants and fracture management products. Orthopaedic reconstruction implants restore joint function lost to disease or trauma in joints such as knees, hips, shoulders and elbows. Fracture management products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body's natural healing process.

General Information

ZIMMER HOLDINGS

345 East Main Street Warsaw, IN 46580 Phone: 574-267-6131 Fax: 574-372-4988 Web: www.zimmer.com Email: investor.zimmer.com

Industry	MED PRODUCTS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	01/28/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	57.96
52 Week High	58.47
52 Week Low	30.67
Beta	1.07
20 Day Moving Average	1,682,699.38
Target Price Consensus	57.81

% Price Change
4 Week	4.04
12 Week	18.68
YTD	40.82

% Price Change Relative to S&P 500
4 Week	2.92
12 Week	11.89
YTD	16.55

Share Information
Shares Outstanding (millions)	214.30
Market Capitalization (millions)	12,198.18
Short Ratio	1.34
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	1.08
Current Year EPS Consensus Estimate	3.90
Estimated Long-Term EPS Growth Rate	8.20
Next EPS Report Date	01/28/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.76
30 Days Ago	3.00
60 Days Ago	2.94
90 Days Ago	2.83

Fundamental Ratios

P/E
Current FY Estimate:	14.59
Trailing 12 Months:	14.86
PEG Ratio	1.79

EPS Growth
vs. Previous Year	-9.28%
vs. Previous Quarter	-12.00%

Sales Growth
vs. Previous Year	2.46%
vs. Previous Quarter:	-4.34%

Price Ratios
Price/Book	2.04
Price/Cash Flow	10.66
Price / Sales	3.04

ROE
09/30/09	14.59
06/30/09	15.36
03/31/09	15.94

ROA
09/30/09	11.34
06/30/09	11.98
03/31/09	12.49

Current Ratio
09/30/09	3.62
06/30/09	3.48
03/31/09	3.12

Quick Ratio
09/30/09	2.18
06/30/09	2.01
03/31/09	1.77

Operating Margin
09/30/09	20.86
06/30/09	21.76
03/31/09	21.95

Net Margin
09/30/09	24.98
06/30/09	26.10
03/31/09	26.27

Pre-Tax Margin
09/30/09	24.98
06/30/09	26.10
03/31/09	26.27

Book Value
09/30/09	27.90
06/30/09	26.99
03/31/09	24.99

Inventory Turnover
09/30/09	1.00
06/30/09	1.02
03/31/09	1.11

Debt-to-Equity
09/30/09	0.10
06/30/09	0.11
03/31/09	0.12

Debt to Capital
09/30/09	9.12
06/30/09	10.12
03/31/09	10.63


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research